The development of antibacterial drugs based on novel chemotypes is essential to the future management of serious drug resistant infections. We herein report the design, synthesis and SAR of a novel series of N-ethylurea inhibitors based on a pyridine-3-carboxamide scaffold targeting the ATPase sub-unit of DNA gyrase. Consideration of structural aspects of the GyrB ATPase site has aided the development of this series resulting in derivatives that demonstrate excellent enzyme inhibitory activity coupled to potent Gram positive antibacterial efficacy
DNA gyrase and topoisomerase IV are type IIa topoisomerases that are essential bacterial enzymes req...
DNA gyrase and topoisomerase IV are type IIa topoisomerases that are essential bacterial enzymes req...
Due to the rapid development of antimicrobial resistance, the discovery of new antibacterials is ess...
ATP-competitive inhibitors of DNA gyrase and topoisomerase IV are among the most interesting classes...
ATP-competitive inhibitors of DNA gyrase and topoisomerase IV are among the most interesting classes...
The ATP binding site located on the subunit B of DNA gyrase is an attractive target for the developm...
The ATP binding site located on the subunit B of DNA gyrase is an attractive target for the developm...
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but ...
According to the World Health Organization (WHO), approximately 1.7 million deaths per year are caus...
According to the World Health Organization (WHO), approximately 1.7 million deaths per year are caus...
According to the World Health Organization (WHO), approximately 1.7 million deaths per year are caus...
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but ...
Development of novel DNA gyrase B inhibitors is an important field of antibacterial drug discovery w...
Previously we have reported on a series of pyridine-3-carboxamide inhibitors of DNA gyrase and DNA t...
Development of novel DNA gyrase B inhibitors is an important field of antibacterial drug discovery w...
DNA gyrase and topoisomerase IV are type IIa topoisomerases that are essential bacterial enzymes req...
DNA gyrase and topoisomerase IV are type IIa topoisomerases that are essential bacterial enzymes req...
Due to the rapid development of antimicrobial resistance, the discovery of new antibacterials is ess...
ATP-competitive inhibitors of DNA gyrase and topoisomerase IV are among the most interesting classes...
ATP-competitive inhibitors of DNA gyrase and topoisomerase IV are among the most interesting classes...
The ATP binding site located on the subunit B of DNA gyrase is an attractive target for the developm...
The ATP binding site located on the subunit B of DNA gyrase is an attractive target for the developm...
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but ...
According to the World Health Organization (WHO), approximately 1.7 million deaths per year are caus...
According to the World Health Organization (WHO), approximately 1.7 million deaths per year are caus...
According to the World Health Organization (WHO), approximately 1.7 million deaths per year are caus...
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but ...
Development of novel DNA gyrase B inhibitors is an important field of antibacterial drug discovery w...
Previously we have reported on a series of pyridine-3-carboxamide inhibitors of DNA gyrase and DNA t...
Development of novel DNA gyrase B inhibitors is an important field of antibacterial drug discovery w...
DNA gyrase and topoisomerase IV are type IIa topoisomerases that are essential bacterial enzymes req...
DNA gyrase and topoisomerase IV are type IIa topoisomerases that are essential bacterial enzymes req...
Due to the rapid development of antimicrobial resistance, the discovery of new antibacterials is ess...